53179-10-5

Basic information

• Product Name: Fluperamide
• Synonyms: Fluperamidium;4-[4-Chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutanamide;R-18910;4-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-di(phenyl)butyramide;4-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-di(phenyl)butanamide;4-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-di(phenyl)butanamide
• CAS NO: 53179-10-5
• Molecular Formula: C₃₀H₃₂ClF₃N₂O₂
• Molecular Weight: 545.042
• Mol File: 53179-10-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 667.7°Cat760mmHg
• Flash Point: 357.6°C
• Appearance: /
• Density: 1.252g/cm³
• Vapor Pressure: 9.67E-19mmHg at 25°C
• Refractive Index: 1.568
• CAS DataBase Reference: Fluperamide(CAS DataBase Reference)
• NIST Chemistry Reference: Fluperamide(53179-10-5)
• EPA Substance Registry System: Fluperamide(53179-10-5)

Safety Data

• Hazardous Substances Data: 53179-10-5(Hazardous Substances Data)

Usage

Uses

Antiperistaltic.

InChI:InChI=1/C30H32ClF3N2O2/c1-35(2)27(37)29(22-9-5-3-6-10-22,23-11-7-4-8-12-23)17-20-36-18-15-28(38,16-19-36)24-13-14-26(31)25(21-24)30(32,33)34/h3-14,21,38H,15-20H2,1-2H3

Upstream product

• 21928-50-7 4-[4-chloro-3-trifluoromethylphenyl]-4-piperidinol 
• 37743-18-3 N-(dihydro-3,3-diphenyl-2(3H)-furanylidene)-N-methylmethanaminium bromide 
• 37742-98-6 4-Bromo-2,2-diphenylbutyric acid 
• 50650-44-7 4-bromo-2,2-diphenylbutyric acid chloride 

Relevant articles and documents

Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor

Small molecule mu agonists based on the 4-phenyl piperidine scaffold were designed and synthesized to further investigate the therapeutic potential of loperamide analogs. The resulting compounds show excellent agonistic activity towards the human mu receptor with interesting SAR trends within the series. Small molecule mu agonists based on the 4-phenyl piperidine scaffold were designed and synthesized to further investigate the therapeutic potential of loperamide analogs. The resulting compounds show excellent agonistic activity towards the human mu receptor with interesting SAR trends within the series.